Monday, November 23, 2026

National Cancer Center confirms potential for early detection of leukemia relapse through personalized genetic testing

Input
2026-10-13 12:56:39
Updated
2026-10-13 12:56:39
Professor Shim Hyo-eun of the National Cancer Center’s Department of Laboratory Medicine (left) and Professor Lee Hye-won of its Department of Hematology and Oncology. Provided by the National Cancer Center
[Financial News] A research team at the National Cancer Center has reported the potential for detecting signs of acute myeloid leukemia relapse early by tracking each patient’s genetic mutations. Leukemia-related genetic signals appeared in patients nearing relapse after hematopoietic stem cell transplantation, while no such signals were observed in patients who did not relapse.
 The National Cancer Center announced on the 13th that a research team led by Professor Shim Hyo-eun of its Department of Laboratory Medicine had confirmed these findings.
 Acute myeloid leukemia is a blood cancer caused by abnormalities in blood-forming cells. Because it can relapse even after treatment, it is important to monitor for residual cancer cells.
 The research team used digital PCR (ddPCR) testing to detect specific genetic mutations remaining in extremely small amounts in the blood or bone marrow. The approach tracks different genetic mutations in each patient to examine their association with relapse.
 The team tested 37 of the 49 patients treated in 2024–2025 who were found to have specific genetic mutations, and analyzed results from the 11 patients who could undergo repeated testing after hematopoietic stem cell transplantation.
 The results from blood and bone marrow tests showed 95.2% agreement. Measurements of genetic mutations also showed a strong correlation with results from next-generation sequencing (NGS), which analyzes multiple genes at once. In particular, leukemia-related genetic signals appeared as relapse drew near, while no such signals were detected during follow-up in patients who did not relapse.
 However, detecting a genetic signal does not necessarily mean that relapse will occur. Some genetic mutations can appear without being directly related to relapse, so results from other tests should also be considered, including bone marrow tests and chimerism tests, which assess the degree to which donor cells have engrafted.
 Professor Shim said, "This study confirmed the potential for digital PCR testing to be used to closely monitor changes associated with leukemia relapse after hematopoietic stem cell transplantation. We will study more patients and further develop the test for use in clinical practice."
 The study was supported by the National Cancer Center’s Public Interest Cancer Research Program. The findings were presented at the 2026 conference of the International Congress of Blood and Marrow Transplantation (ICBMT), where Professor Shim received the Best Poster Presentation Award. The corresponding author is Professor Lee Hye-won of the Department of Hematology and Oncology.
[email protected] Jeong Sang-hee Reporter